Discounted Cash Flow Rating

Buy

Return on Equity Rating

Strong Sell

Debt to Equity Rating

Neutral

Price to Earnings Rating

Sell

Analyst Rating

Neutral

Simple Moving Average

Neutral

Exponential Moving Average

Neutral

Relative Strength Index

Standard Deviation

Strong Sell

Williams %R

Strong Buy

Average Directional Index

Strong Sell

Insider Trading

Neutral

Wall Street Data Solutions Rating

Sell

C

Freeline Therapeutics Holdings plc American Depositary Shares (FRLN)

https://www.freeline.life

Freeline Therapeutics Holdings PLC is a clinical-stage biotechnology company developing transformative adeno-associated virus (AAV) vector-mediated gene therapies for patients suffering from inherited systemic debilitating diseases. Its lead product candidates are FLT180a for the treatment of hemophilia B, FLT190 for the treatment of Fabry disease and FLT201 for the treatment of Gaucher disease Type 1.

Current Price

---.--

% Change Today

0.00%

Change Amt. Today

0.00

Active Status

Active

Listing Date

08/07/2020

Market Cap

28,283,096

Shares Outstanding

65,370,000

Weighted SO

4,357,947

Total Employees

N/A

Upcoming Earnings

N/A

Similar Tickers

CNSP --.--%

ZVSA --.--%

EFTR --.--%

VECT --.--%

AVRO --.--%

IMMX --.--%

HEPA --.--%

NAVB --.--%

SONN --.--%

Beta

0.6600

Last Div

0.0000

Range

2.11-8.745

Chg

0.0100

Avg Vol

28144

Mkt Cap

28283096

Exch

NASDAQ

Country

GB

Phone

44 14 3890 6870

DCF Diff

-3.9858

DCF

10.4658

Div Yield

0.0000

P/S

45.4712

EV Multiple

-0.0335

P/FV

0.9415

Div Yield %

0.0000

P/E

-0.5664

PEG

-0.0092

Payout

0.0000

Current Ratio

1.9452

Quick Ratio

1.8467

Cash Ratio

1.6852

DSO

1656.5836

DIO

192.2088

Op Cycle

1848.7924

DPO

1946.6146

CCC

-97.8222

Gross Margin

-1.3447

Op Margin

-109.1254

Pretax Margin

-79.5032

Net Margin

-80.2765

Eff Tax Rate

-0.0097

ROA

-1.0145

ROE

-1.1068

ROCE

-2.1384

NI/EBT

1.0097

EBT/EBIT

0.7285

EBIT/Rev

-109.1254

Debt Ratio

0.0810

D/E

0.1328

LT Debt/Cap

0.0536

Total Debt/Cap

0.1172

Int Coverage

2.0714

CF/Debt

-16.1091

Equity Multi

1.6384

Rec Turnover

0.2203

Pay Turnover

0.1875

Inv Turnover

1.8990

FA Turnover

0.0496

Asset Turnover

0.0126

OCF/Share

-14.7412

FCF/Share

-15.7855

Cash/Share

6.7581

OCF/Sales

-103.2846

FCF/OCF

1.0708

CF Coverage

-16.1091

ST Coverage

-28.1028

CapEx Coverage

-14.1162

Div&CapEx Cov

-14.1162

P/BV

0.9415

P/B

0.9415

P/S

45.4712

P/E

-0.5664

P/FCF

-0.4111

P/OCF

-0.4403

P/CF

-0.4403

PEG

-0.0092

P/S

45.4712

EV Multiple

-0.0335

P/FV

0.9415

DPS

0.0000

Latest Headlines (EST)

GlobeNewswire Inc. Nov 22, 07:30 Syncona to Acquire Freeline Therapeutics GlobeNewswire Inc. Oct 25, 02:01 Freeline Presents Positive New Data from Phase 1/2 GALILEO-1 Trial of FLT201, Its Novel Gene Therapy Candidate, in Gaucher Disease at ESGCT 30th Annual Congress GlobeNewswire Inc. Oct 25, 02:01 Freeline Presents Positive New Data from Phase 1/2 GALILEO-1 Trial of FLT201, Its Novel Gene Therapy Candidate, in Gaucher Disease at ESGCT 30th Annual Congress GlobeNewswire Inc. Oct 25, 02:01 Freeline Presents Positive New Data from Phase 1/2 GALILEO-1 Trial of FLT201, Its Novel Gene Therapy Candidate, in Gaucher Disease at ESGCT 30th Annual Congress

Revenue Product Segmentation